Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 08, 2021

            Details:

            The global clinical trial will assess the efficacy, safety, and pharmacokinetics (PK) profile of CBP-201, was designed to enroll 220 subjects and is being conducted at 60 sites across the US, China, Australia, and New Zealand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OQL011

            Therapeutic Area: Dermatology Product Name: OQL011

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Shiyu Capital

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing March 31, 2021

            Details:

            Proceeds from the financing will support the Phase II clinical trial of the company's leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Renaissance Capital

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 26, 2021

            Details:

            Connect's lead candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD) and asthma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMG-20

            Therapeutic Area: Dermatology Product Name: IMG-20

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vertex Ventures

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing November 09, 2020

            Details:

            The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. IMG-20, Inmagene’s most advanced drug candidate, is about to enter the global registration trials for multiple indications.